10.02.2010 • News

Boehringer to Buy Rest of Japan's SSP

German drug company Boehringer Ingelheim is in talks to make Japanese subsidiary SSP wholly-owned in a deal worth more than $335 million, the Nikkei newspaper reported. Boehringer currently owns 60% of SSP, a maker of over-the-counter drugs. Boehringer is expected to buy the remaining stake in a tender offer as early as the end of this month, the Nikkei said. Tetsuya Owari, a spokesman for Boehringer in Japan, said nothing had been decided. He declined to elaborate.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read